Background The incidence of vascular cognitive impairment(VCI)is high in patients suffering from ischaemic stroke or transient ischaemic attack(TIA)or with vascular risk factors.Effective prevention strategies for VCI...Background The incidence of vascular cognitive impairment(VCI)is high in patients suffering from ischaemic stroke or transient ischaemic attack(TIA)or with vascular risk factors.Effective prevention strategies for VCI remain limited.Anaemia or low haemoglobin was found as an independent risk factor for adverse outcomes after acute stroke.Anaemia or low haemoglobin was possibly associated with an increased risk of poststroke cognitive impairment.Whether supplement of ferrous iron to correct anaemia reduces the risk of VCI and improves adverse outcomes in patients with ischaemic cerebrovascular disease remains uncertain.Aim We aim to introduce the design and rationale of the safety and efficacy of Ferrous iron on the prevention of Vascular cOgnitive impaiRment in patients with cerebral Infarction or TIA(FAVORITE)trial.Design FAVORITE is a randomised,placebo-controlled,double-blind,multicentre trial that compares supplement of ferrous iron with placebo for recent minor stroke/TIA patients complicated with mild anaemia or iron deficiency:Ferrous succinate sustained-release tablet 0.2 g(corresponding to 70 mg of elemental iron)once daily after or during breakfast for 12 weeks or placebo with much the same colour,smell and size as ferrous iron once daily during or after breakfast for 12 weeks.All paticipants will be followed within the next year.Study outcomes The primary effective outcome is the incidence of VCI at 3 months after randomisation and the primary safety outcome includes any gastrointestinal adverse event during 3 months.Discussion The FAVORITE trial will clarify whether supplement of ferrous iron to correct low haemoglobin reduces the risk of VCI in patients with recent ischaemic stroke or TIA complicated with mild anaemia or iron deficiency compared with placebo.展开更多
基金funded by the National Key R&D Program of China(2018YFC1312300)the National Science and Technology Major Project(2017ZX09304018).
文摘Background The incidence of vascular cognitive impairment(VCI)is high in patients suffering from ischaemic stroke or transient ischaemic attack(TIA)or with vascular risk factors.Effective prevention strategies for VCI remain limited.Anaemia or low haemoglobin was found as an independent risk factor for adverse outcomes after acute stroke.Anaemia or low haemoglobin was possibly associated with an increased risk of poststroke cognitive impairment.Whether supplement of ferrous iron to correct anaemia reduces the risk of VCI and improves adverse outcomes in patients with ischaemic cerebrovascular disease remains uncertain.Aim We aim to introduce the design and rationale of the safety and efficacy of Ferrous iron on the prevention of Vascular cOgnitive impaiRment in patients with cerebral Infarction or TIA(FAVORITE)trial.Design FAVORITE is a randomised,placebo-controlled,double-blind,multicentre trial that compares supplement of ferrous iron with placebo for recent minor stroke/TIA patients complicated with mild anaemia or iron deficiency:Ferrous succinate sustained-release tablet 0.2 g(corresponding to 70 mg of elemental iron)once daily after or during breakfast for 12 weeks or placebo with much the same colour,smell and size as ferrous iron once daily during or after breakfast for 12 weeks.All paticipants will be followed within the next year.Study outcomes The primary effective outcome is the incidence of VCI at 3 months after randomisation and the primary safety outcome includes any gastrointestinal adverse event during 3 months.Discussion The FAVORITE trial will clarify whether supplement of ferrous iron to correct low haemoglobin reduces the risk of VCI in patients with recent ischaemic stroke or TIA complicated with mild anaemia or iron deficiency compared with placebo.
